Biological characterization of AT7519, a small-molecule inhibitor of cyclin-dependent kinases, in human tumor cell lines.
about
Targeting cyclin-dependent kinases in human cancers: from small molecules to Peptide inhibitorsCDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours.Induction of eosinophil apoptosis by the cyclin-dependent kinase inhibitor AT7519 promotes the resolution of eosinophil-dominant allergic inflammationIn silico design and biological evaluation of a dual specificity kinase inhibitor targeting cell cycle progression and angiogenesisArylazopyrazole AAP1742 inhibits CDKs and induces apoptosis in multiple myeloma cells via Mcl-1 downregulation.The impact of CDK inhibition in human malignancies associated with pronounced defects in apoptosis: advantages of multi-targeting small molecules.Inhibition of HSP90 by AT13387 delays the emergence of resistance to BRAF inhibitors and overcomes resistance to dual BRAF and MEK inhibition in melanoma modelsA Phase I study of cyclin-dependent kinase inhibitor, AT7519, in patients with advanced cancer: NCIC Clinical Trials Group IND 177.6,7,4'-trihydroxyisoflavone inhibits HCT-116 human colon cancer cell proliferation by targeting CDK1 and CDK2.Targeting cell cycle regulators in hematologic malignancies.Cyclin Dependent Kinase 9 Inhibitors for Cancer TherapyCyclin-Dependent Kinase Inhibitor AT7519 as a Potential Drug for MYCN-Dependent NeuroblastomaCDK9 inhibitors selectively target estrogen receptor-positive breast cancer cells through combined inhibition of MYB and MCL-1 expression.Cancer and pregnancy: parallels in growth, invasion, and immune modulation and implications for cancer therapeutic agents.Genetic and pharmacological inhibition of CDK9 drives neutrophil apoptosis to resolve inflammation in zebrafish in vivo.Cyclin-dependent kinases regulate apoptosis of intestinal epithelial cells.Cell cycle proteins as promising targets in cancer therapyKinase inhibitors as potential agents in the treatment of multiple myeloma.Cyclin-dependent kinase inhibitors: a survey of recent patent literature.Novel potent pharmacological cyclin-dependent kinase inhibitors.A guide to picking the most selective kinase inhibitor tool compounds for pharmacological validation of drug targets.Cyclin dependent kinases in cancer: potential for therapeutic intervention.Perspective of cyclin-dependent kinase 9 (CDK9) as a drug target.Deregulations in the cyclin-dependent kinase-9-related pathway in cancer: implications for drug discovery and development.Transcription inhibition as a therapeutic target for cancerOverview of cyclins D1 function in cancer and the CDK inhibitor landscape: past and present.Potential Clinical Uses of CDK Inhibitors: Lessons from Synthetic Lethality Screens.AT7519, A novel small molecule multi-cyclin-dependent kinase inhibitor, induces apoptosis in multiple myeloma via GSK-3beta activation and RNA polymerase II inhibition.Recent progress of cyclin-dependent kinase inhibitors as potential anticancer agents.The HSP90 inhibitor, AT13387, is effective against imatinib-sensitive and -resistant gastrointestinal stromal tumor models.Design and synthesis of pyrazole/isoxazole linked arylcinnamides as tubulin polymerization inhibitors and potential antiproliferative agents.Replication factor C3 is a CREB target gene that regulates cell cycle progression through the modulation of chromatin loading of PCNA.Investigational drugs targeting cyclin-dependent kinases for the treatment of cancer: an update on recent findings (2013-2016).Inhibitors of cyclin-dependent kinases as cancer therapeutics.Systematic Kinase Inhibitor Profiling Identifies CDK9 as a Synthetic Lethal Target in NUT Midline Carcinoma.Anti-cancer activity of anti-GLUT1 antibody-targeted polymeric micelles co-loaded with curcumin and doxorubicin.An in silico exploration of the interaction mechanism of pyrazolo[1,5-a]pyrimidine type CDK2 inhibitors.Characterization of CDK(5) inhibitor, 20-223 (aka CP668863) for colorectal cancer therapy.CDK9 inhibitors in acute myeloid leukemia.The CDK inhibitor AT7519M in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and mantle cell lymphoma. A Phase II study of the Canadian Cancer Trials Group.
P2860
Q26827580-79C7BCA5-7771-4BC5-AADD-AB699544B89FQ27853338-62B8BCFF-76FE-4D5E-87C2-872FDE30F66CQ28477314-FA57CFF9-865E-4DB3-AC07-F78B987D46E2Q28544931-508F3E95-CBCE-4706-A1D0-74570B0F181EQ31160552-DA565CC8-9530-4109-AA9F-DA075CF5D482Q34195072-2ACA16E8-AFD5-4DC1-84A7-99A9D93EDF6BQ34677194-B8457B5E-2F31-49FA-8479-6C9A35D31493Q34687067-9463F16E-D3E4-4F6D-AB73-E0C38655B2C0Q34734125-60FE893D-5A8E-4CBA-ADE9-A037AC6D7966Q35334436-57BE0B4D-2D98-4588-B570-FC35D45BC09CQ36015334-C5180FF4-F9BD-4870-8235-4BC74A58A5A6Q36281460-899FE995-DA9C-498A-8D0F-1AF4D5BEAF9BQ36962507-40C655E0-1A85-45E0-94F4-6CAEB9D2C3BBQ37406706-EAF53FC7-A5BF-414D-8F25-C1DC6FC3BC6CQ37408454-140AFB62-0F7E-4211-B337-6B213BE7C564Q37622948-2E65AA87-C2FB-47FC-BBC5-71561F3FF73FQ37693690-45BADEFD-922A-449A-A627-0B9BF200E23BQ37697253-85312707-B048-486E-88ED-2CA9AD8A6498Q37697797-E3644D11-B447-4118-AD0F-E25D97C3F5DEQ37855812-73D4B4AB-1532-4BBD-966E-2767066A5D3DQ37976467-58D06851-4E41-47EF-B828-68954A3DAD13Q37987789-1821F9DA-3D84-4F64-A47E-C442E06E8BBAQ38008733-1789BED4-A972-49C5-9C53-579EDFA3F161Q38120534-50304B73-46D1-4813-9855-B3BECCD03C7FQ38161381-DED54F7F-3CBC-4C45-BEA2-447EE26D4733Q38175443-A88B1B92-F168-48F2-AAAC-81221DFE6A75Q38538589-B1D7CF6F-51EB-4618-A462-172CB0DDA05BQ38597474-53BC6411-7C0F-475A-ACF6-EB4E75B2B968Q38806786-A9059ABA-4C6E-42BB-8399-0C6AE7A6F275Q38833685-5C83EC6C-E883-4E6C-9DC1-E26F2B028996Q38841186-7FAEF3AE-2891-42FE-B2AC-A2AE139E3A6BQ38925416-D1617D06-7839-4D22-8AED-2D5307DC9C18Q38949247-7D3A94FD-55F5-495E-80A0-1D9FEF7E1B06Q39125016-294D43FC-D608-4B4B-A958-594EAA374A0AQ42367759-1DEF4058-1D00-4749-9A40-4581C38E5AB6Q44244964-57072FA3-7E6C-4402-BB2B-605821A0AC03Q45327842-82FEF652-F01F-4E26-9BFB-A31762A1F001Q49536215-C1D25F16-9C8B-4217-A8DC-A65D812BE27EQ50318294-BC166DF0-8FFF-4598-8B29-B37E50626359Q53006177-60B726A8-5CCA-4AE7-8205-789141B4B5CD
P2860
Biological characterization of AT7519, a small-molecule inhibitor of cyclin-dependent kinases, in human tumor cell lines.
description
2009 nî lūn-bûn
@nan
2009 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Biological characterization of ...... es, in human tumor cell lines.
@ast
Biological characterization of ...... es, in human tumor cell lines.
@en
type
label
Biological characterization of ...... es, in human tumor cell lines.
@ast
Biological characterization of ...... es, in human tumor cell lines.
@en
prefLabel
Biological characterization of ...... es, in human tumor cell lines.
@ast
Biological characterization of ...... es, in human tumor cell lines.
@en
P2093
P1476
Biological characterization of ...... es, in human tumor cell lines.
@en
P2093
David M Cross
Donna-Michelle Smith
E Jonathan Lewis
John F Lyons
Matthew S Squires
Neil T Thompson
Nicola G Wallis
Ruth E Feltell
P304
P356
10.1158/1535-7163.MCT-08-0890
P577
2009-01-27T00:00:00Z